{"title":"吉西他滨-(C4 -酰胺)-[抗egfr]联合表柔比星-(C3 -酰胺)-[抗her2 /neu]抗化疗耐药乳腺腺癌(SKBr-3)的肿瘤细胞毒性及甲苯达唑的互补作用","authors":"C.P. Coyne","doi":"10.17303/jcrto.2013.2.203","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"24 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4 -amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3 -amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole\",\"authors\":\"C.P. Coyne\",\"doi\":\"10.17303/jcrto.2013.2.203\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":15189,\"journal\":{\"name\":\"Journal of Cancer Research and Therapeutic Oncology\",\"volume\":\"24 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Research and Therapeutic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17303/jcrto.2013.2.203\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Therapeutic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17303/jcrto.2013.2.203","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4 -amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3 -amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole